度普利尤单抗在非特应性皮炎皮肤病中的应用进展OA
Progress in the application of dupilumab for non-atopic dermatitis
度普利尤单抗通过靶向阻断IL-4 和IL-13 的信号传导而抑制Th2 介导的炎症反应.近年来,除了被批准用于治疗中重度特应性皮炎,度普利尤单抗在其他炎症性皮肤病的治疗中也展现出了疗效,如结节性痒疹、大疱性类天疱疮、慢性自发性荨麻疹、变应性接触性皮炎、钱币状湿疹、慢性手部湿疹、慢性光化性皮炎、苔藓样皮肤淀粉样变、慢性瘙痒、皮肤免疫相关不良反应、嗜酸性脓疱性毛囊炎、斑秃、瘢痕疙瘩及部分遗传性皮肤病等.本文综述度普利尤单抗在非特应性皮炎皮肤病中的应用进展,旨在为临床医生提供更多理论依据和治疗选择.
Dupilumab inhibits Th2-mediated inflammatory responses by specifically blocking the signaling pathways of interleukin-4 and interleukin-13.Recently,in addition to its approved indication for the treatment of moderate-to-severe atopic dermatitis,dupilumab has also shown effi-cacy in treating other inflammatory skin diseases,such as prurigo nodularis,bullous pemphigoid,chronic spontaneous urticaria,allergic contact dermatitis,nummular eczema,chronic hand ecze-ma,chronic actinic dermatitis,lichen amyloidosis,chronic pruritus,cutaneous immune-related adverse events,eosinophilic pustular folliculitis,alopecia areata,keloids,and some genetic skin diseases.This article reviews the progress of dupilumab in the treatment of non-atopic dermatitis skin diseases to provide more theoretical basis and treatment options for the clinicians.
史希武;刘晴;王秀丽;韩杨;胡竹林
安庆市立医院,安徽 安庆 246000安庆市立医院,安徽 安庆 246000安庆市立医院,安徽 安庆 246000安庆市立医院,安徽 安庆 246000安庆市立医院,安徽 安庆 246000
炎症性皮肤病度普利尤单抗白细胞介素-4白细胞介素-13
inflammatory skin diseasesdupilumabinterleukin-4interleukin-13
《皮肤性病诊疗学杂志》 2026 (1)
72-80,封3,10
安徽省卫生健康科研项目(AHWJ2023A30066)
评论